Peptide News NetworkThe source for peptide knowledge and current events: research, clinical trials, regulation, and industry reporting.https://peptidenewsnetwork.com/BPC-157 Goes Before the FDA: What to Watch at the July Compounding Hearinghttps://peptidenewsnetwork.com/articles/bpc-157-503a-compounding-hearing/https://peptidenewsnetwork.com/articles/bpc-157-503a-compounding-hearing/On July 23 and 24, an FDA advisory committee reviews seven peptides, including BPC-157, TB-500, and Semax, for the list that decides which substances pharmacists may legally compound.Sun, 12 Jul 2026 00:00:00 GMTRegulationGLP-1, GIP, Glucagon, Amylin: The Four Gut Hormones Behind the New Drugshttps://peptidenewsnetwork.com/articles/gut-hormones-explainer/https://peptidenewsnetwork.com/articles/gut-hormones-explainer/Every headline drug in metabolic medicine is built from the same short list of hormones. Here is what each one does, and why companies keep combining them.Wed, 08 Jul 2026 00:00:00 GMTExplainersA Peptide Company Just Set the Record for the Largest Venture-Backed Biotech IPOhttps://peptidenewsnetwork.com/articles/parabilis-largest-biotech-ipo/https://peptidenewsnetwork.com/articles/parabilis-largest-biotech-ipo/Parabilis Medicines' Nasdaq debut, priced at a $670 million offering and closing at $770.5 million, puts a stabilized-peptide platform atop a ranking long ruled by antibody and small-molecule firms.Thu, 11 Jun 2026 00:00:00 GMTIndustryNovo Nordisk's Zenagamtide Pairs GLP-1 With Amylin in One Molecule, Cutting A1C and Weight in a Phase 2 Trialhttps://peptidenewsnetwork.com/articles/zenagamtide-amylin-glp1/https://peptidenewsnetwork.com/articles/zenagamtide-amylin-glp1/The first single-molecule drug to combine GLP-1 and amylin activation showed meaningful glucose and weight effects in type 2 diabetes, an early signal of the field's move into amylin-based therapy.Fri, 05 Jun 2026 00:00:00 GMTClinical TrialsRetatrutide, Lilly's Triple-Hormone Agonist, Posts 28% Weight Loss in Its Pivotal Obesity Trialhttps://peptidenewsnetwork.com/articles/retatrutide-triumph-1/https://peptidenewsnetwork.com/articles/retatrutide-triumph-1/The largest and longest trial yet of a drug that hits three gut-hormone receptors at once points to a new efficiency ceiling for obesity medicines, though these are topline results, not yet peer-reviewed.Thu, 21 May 2026 00:00:00 GMTClinical TrialsFDA Proposes 'No Clinical Need' to Compound GLP-1 Drugs From Bulk Ingredientshttps://peptidenewsnetwork.com/articles/fda-glp1-compounding-bulk/https://peptidenewsnetwork.com/articles/fda-glp1-compounding-bulk/The agency's proposed determination would bar outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk active ingredient, unless a new shortage intervenes.Fri, 01 May 2026 00:00:00 GMTRegulation